Modern Concepts of Clinical and Diagnostic Criteria for Premature Ovarian Failure (Literature Review)

Premature ovarian insufficiency (POI) is a life-changing diagnosis with profound physical and psychological consequences. POI, defined as amenorrhea due to the loss of ovarian function before 40 years of age, can occur spontaneously or be secondary to medical therapies. POI is associated with cardiovascular morbidity, osteoporosis and premature mortality. General practitioners play an important role in the evaluation and long-term management of women with POI. Before getting to the gynecologist, more than 50 % of women, on average, turn to three different specialists. Success of early diagnosis, possibility of timely prescription of hormone therapy, and monitoring of the long-term effects of hypoestrogenism depend on the general practitioner’s knowledge of this pathology. The purpose of this review was to systematize the available data on modern clinical diagnostic criteria for POI, for the early detection and prevention of reproductive losses, as well as improving the quality of life of women. An information search was carried out using Internet resources (PubMed, Web of Science, eLibrary.Ru), literary sources for the period 2015–2019 were analyzed. As a result of the analysis of the literature data, a step-by-step diagnosis of pathology was described, the main shortcomings of the main marker for assessing ovarian function – folliclestimulating hormone – were identified and listed. And also the advantages of  anti-Müllerian hormone in the early diagnosis of ovarian insufficiency are considered.

premature ovarian failure, premature ovarian insufficiency, ovarian reserve, diagnosis of POI, infertility, amenorrhea, anti-Müllerian hormone, follicle-stimulating hormone

1. Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, et al. ESHRE guideline: Management of women with premature ovarian insufficiency. Hum Reprod 2016; 31(5): 926-937. doi: 10.1093/humrep/dew027

2. Tabeyeva GI, Shamilova NN, Zhakhur NA, Pozdnyakova AA, Marchenko LA. Premature ovarian failure is an enigma of the 21st century. Obstet Gynecol. 2013 (12): 16-21. (In Russ.)

3. Fraison E, Crawford G, Casper G, Harris V, Ledger W. Pregnancy following diagnosis of premature ovarian insufficiency: A systematic review. Reprod Biomed Online. 2019; 39(3): 467-476. doi: 10.1016/j.rbmo.2019.04.019

4. Tsaregorodtseva MV, Novikova YaS, Podolyan OF. Premature ovarian failure: New therapeutic options. Klimakteriy. 2016; (3): 26-31. (In Russ.)

5. Torrealday S, Kodaman P, Pal L. Premature ovarian insufficiency – an update on recent advances in understanding and management. F1000Res. 2017;6:2069 doi: 10.12688/f1000research.11948.1

6. Baber RJ, Panay N, Fenton A, IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-150. doi: 10.3109/13697137.2015.1129166

7. Kovalenko II, Danusevich IN, Nadelyaeva YaG, Lazareva LM, Atalyan AV, Suturina LV. Characteristics of patients with premature ovarian insufficiency according to the patient registry. Mezhdunarodnyy zhurnal prikladnykh i fundamentalnykh issledovaniy. 2017; (11-1): 53-56. (In Russ.)

8. Cox L, Liu JH. Primary ovarian insufficiency: An update. Int J Womens Health. 2014; (6): 235-243. doi: 10.2147/IJWH.S37636

9. Komorowska B. Autoimmune premature ovarian failure. Prz Menopauzalny. 2016; 15(4): 210-214. doi: 10.5114/pm.2016.65666

10. Kruszyńska A, Słowińska-Srzednicka J. Anti-Müllerian hormone (AMH) as a good predictor of time of menopause. Prz Menopauzalny. 2017; 16(2): 47-50. doi: 10.5114/pm.2017.68591

11. Vincent A, Farrell E. Premature menopause. In: Dvornyk V (ed.). Current topics in menopause. Sharjah: Bentham Science; 2013: 414-441. doi: 10.2174/97816080545341130101

12. Bilgin EM, Kovanci E. Genetics of premature ovarian failure. Current Opinion in Obstet Gynecol. 2015; 27(3): 167-174. doi: 10.1097/GCO.0000000000000177

13. Pastore LM, Johnson J. The FMR1 gene, infertility, and reproductive decision-making: A review. Front Genet. 2014; (5): 195. doi: 10.3389/fgene.2014.00195

14. Maclaran K, Nick P. Current concepts in premature ovarian insufficiency. Womens Health (Lond). 2015; 11(2): 169-182. doi: 10.2217/whe.14.82

15. Hudson MM. Reproductive outcomes for survivors of childhood cancer. Obstet Gynecol. 2010; 116(5): 1171-1183. doi: 10.1097/AOG.0b013e3181f87c4b

16. Nguyen HH, Milat F, Vincent A. Premature ovarian insufficiency in general practice: Meeting the needs of women. Aust Fam Physician.2017; 46(6): 360-366.

17. Petrov IA, Tikhonovskaja OA, Kuprijanova II, Okorokov AO, Logvinov SV, Petrova MS, et al. Mechanisms of secondary ovarian failure in operations on the pelvic organs (experimental study). Obstetrics, gynecology and reproduction. 2015; 9(4): 6-17. doi: 10.17749/2070-4968.2015.9.4.006-017. (In Russ.)

18. Sosnova EA. Uterine artery embolization in uterine fibroids patients of reproductive age and its role in shaping of autoimmune oophoritis. V.F. Snegirev Archives of Obstetrics and Gynecology. 2016; 3(2): 81-87. doi: 10.18821/2313-8726-2016-3-2-81-87. (In Russ.)

19. Atabekoglu C, Taskin S, Kahraman K, Gemici A, Taskin EA, Ozmen B, et al. The effect of total abdominal hysterectomy on serum anti-Müllerian hormone levels: A pilot study. Climacteric. 2012; 15(4): 393-397. doi: 10.3109/13697137.2011.642426

20. Fenton A, Panay N. Does routine gynecological surgery contribute to an early menopause? Climacteric. 2015; 15(1): 1-2. doi: 10.3109/13697137.2012.647623

21. Muzii L, Di Tucci C, Di Feliciantonio M, Galati G, Di Donato V, Mussela A, et al. Antimüllerian hormone is reduced in the presence of ovarian endometriomas: A systematic review and meta-analysis. Fertil Steril. 2018; 110(5): 932-940.e1. doi: 10.1016/j.fertnstert.2018.06.025

22. Amer SA, El Shamy TT, James C, Yosef AH, Mohamed AA. The impact of laparoscopic ovarian drilling on AMH and ovarian reserve: A meta-analysis. Reproduction. 2017; 154(1): R13-R21. doi: 10.1530/REP-17-0063

23. Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE, et al. Pretreatment antimüllerian hormone levels determine rate of post therapy ovarian reserve recovery: Acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013; 99(2): 477-483. doi: 10.1016/j.fertnstert.2012.09.039

24. Fenton AJ. Premature ovarian insufficiency: Pathogenesis and management. J Midlife Health. 2015; 6(4): 147-153. doi: 10.4103/0976-7800.172292

25. Gersak K, Gersak ZM, Turcin A. Reproductive aging: Perimenopause and psychopathological symptoms. In: Drevensek G (ed.). Sex Hormones in Neurodegenerative Processes and Diseases. IntechOpen; 2018: 95-126. doi: 10.5772/intechopen.74159

26. Committee on Gynecologic Practice. Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency. Obstet Gynecol. 2017; 129(5): e134-e141. doi: 10.1097/AOG.0000000000002044

27. Nadelyaeva YaG, Suturina LV. Polycystic ovary syndrome and menopause. Doctor.ru. 2018; 10(154): 47-50. doi: 10.31550/1727-2378-2018-154-10-47-50. (In Russ.)

28. Pluchino N, Carmignani A, Cubeddu A, Santoro A, Cela V, Errasti T. Androgen therapy in women: For whom and when. Arch Gynecol Obstet. 2013; 288(4): 731-737. doi: 10.1007/s00404-013-2969-7

29. Madaeva I, Semenova N, Berdina O, Kolesnikova L. OSA syndrome and sleep structure in climacteric women in East Siberia: Ethnic aspect. Chest. 2019; 155(4): 307a. doi: 10.1016/j.chest.2019.02.298

30. Semenova N, Madaeva I, Kolesnikova L. Insomnia in menopausal women: Racial differences. Maturitas. 2019; 124: 165. doi: 10.1016/j.maturitas.2019.04.149

31. Madaeva IM, Semenova NV, Kolesnikova LI. Ethnic features of sleep disorders in climacteric women. S.S. Korsakov Journal of Neurology and Psychiatry. 2019; 119(4): 44-49. doi: 10.17116/jnevro201911904244. (In Russ.)

32. Tatarchuk TF, Kosei NV, Tutchenko TN. Premature ovarian insufficiency: A syndrome or diagnosis. Clinical lecture. Reproductive endocrinology. 2017; (2): 16-22. doi: 10.18370/2309-4117.2017.34.16-22. (In Russ.)

33. Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOLIntervention questionnaire. Maturitas. 2005; 50(3): 209-221. doi: 10.1016/j.maturitas.2004.06.015

34. Cramer DW, Xu H, Harlow BL. Family history as a predictor of early menopause. Fertil Steril. 1995; 64(4): 740-745. doi: 10.1016/s0015-0282(16)57849-2

35. Luisi S, Orlandini C, Regini C, Pizzo A, Vellucci F, Petraglia F. Premature ovarian insufficiency: from pathogenesis to clinical management. J Endocrinol Invest. 2015; 38(6): 597-603. doi: 10.1007/s40618-014-0231-1

36. Abir R, Fisch B, Nahum R, Orvieto R, Nitke S, Rafael ZB. Turner’s syndrome and fertility: current status and possible putative prospects. Hum Reprod Update. 2001; 7(6): 603-610. doi: 10.1093/humupd/7.6.603

37. Bukman A, Heineman MJ. Ovarian reserve testing and the use of prognostic models in patients with subfertility. Hum Reprod Update. 2001; 7(6): 581-590. doi: 10.1093/humupd/7.6.581

38. Panay N, Kalu E. Management of premature ovarian failure. Best Pract Res Clin Obstet Gynaecol. 2008; 23(1): 129-140. doi: 10.1016/j.bpobgyn.2008.10.008

39. Karkanaki A, Vosnakis C, Panidis D. The clinical significance of anti-mullerian hormone evaluation in gynecological endocrinology. Hormones (Athens). 2011; 10(2): 95-103. doi: 10.14310/horm.2002.1299

40. Kuznetsova IV, Drapkina YuS. Role of anti-müllerian hormone in female reproduction. Medical alphabet. 2017; 2(10): 9-16. (In Russ.)

41. Jeppesen JV, Anderson RA, Kelsey TW, Christiansen SL, Kristensen SG, Jayaprakasan K, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod. 2013; 19(8): 519-527. doi: 10.1093/molehr/gat024

42. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-Müllerian hormone in women. Hum Reprod Update. 2014; 20(3): 370-385. doi: 10.1093/humupd/dmt062

43. Fong SL, Visser JA, Welt CK, de Rijke YB, Eijkemans MJC, Broekmans FJ, et al. Serum anti-müllerian hormone levels in healthy females: A nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab. 2012; 97(12): 4650-4655. doi: 10.1210/jc.2012-1440

44. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WHB. A validated model of serum Anti- Mullerian hormone from conception to menopause. PLoS ONE. 2011; 6(7): e22024. doi: 10.1371/journal.pone.0022024

45. Sahmay S, Usta TA, Erel T, Atakul N, Aydogan B. Elevated LH levels draw a stronger distinction than AMH in premature ovarian insufficiency. Climacteric. 2014; 17(2): 197-203. doi: 10.3109/13697137.2013.870149

46. van Disseldorp J, Lambalk CB, Kwee J, Looman CWN, Eijkemans MJC, Fauser BC, et al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010; 25(1): 221-227. doi: 10.1093/humrep/dep366

47. Randolph Jr JF, Harlow SD, Helmuth ME, Zheng H, McConnell DS. Updated assays for inhibin B and AMH provide evidence for regular episodic secretion of inhibin B but not AMH in the follicular phase of the normal menstrual cycle. Hum Reprod. 2014; 29(3): 592-600. doi: 10.1093/humrep/det447

48. Tal R, Seifer DB. Potential mechanisms for racial and ethnic differences in antimüllerian hormone and ovarian reserve. Int J Endocrinol. 2013; 2013: 818912. doi: 10.1155/2013/818912

49. van Rooij IAJ, Broekmans FJM, Scheffer GJ, Looman CWN, Habbema JDF, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: A longitudinal study. Fertil Steril. 2005; 83(4): 979-987. doi: 10.1016/j.fertnstert.2004.11.029

50. Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: Preliminary results. Reprod Biomed Online. 2010; 20(2): 280-285. doi: 10.1016/j.rbmo.2009.11.010

51. Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Løssl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril. 2010; 94(1): 156-166. doi: 10.1016/j.fertnstert.2009.02.043

52. Perloe M, Levy DP, Sills ES. Strategies for ascertaining ovarian reserve among women suspected of subfertility. Int J Fertil Womens Med. 2000; 45(3): 215-224.

53. Broer SL, Eijkemans MJC, Scheffer GJ, van Rooij IAJ, de Vet A, Themmen APN, et al. Anti-Mullerian hormone predicts menopause: A long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011; 96(8): 2532-2539. doi: 10.1210/jc.2010-2776

54. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary – ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006; 74(2): 100-103. doi: 10.1016/j.contraception.2006.02.006

55. Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril. 2013; 99(4): 963-969. doi: 10.1016/j.fertnstert.2012.11.051